The role of boost and hypofractionation as adjuvant radiotherapy in patients with DCIS: A meta-analysis of observational studies

Radiotherapy and Oncology

Volumn 114, Issue 1, 2015, Pages 50-55

  Nilsson, Cecilia ^a   Valachis, Antonis ^b  

^a Västmanlands County Hospital   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Boost; DCIS; Hypofractionation; Meta analysis; Radiotherapy

Indexed keywords

ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; HUMAN; INTRADUCTAL CARCINOMA; META ANALYSIS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; SYSTEMATIC REVIEW; THERAPY EFFECT; ADJUVANT THERAPY; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; NEOPLASM RECURRENCE, LOCAL; PROCEDURES; RISK FACTOR; SEGMENTAL MASTECTOMY;

BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; NEOPLASM RECURRENCE, LOCAL; OBSERVATIONAL STUDY AS TOPIC; RADIOTHERAPY, ADJUVANT; RISK FACTORS;

EID: 84925270644     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2015.01.001     Document Type: Article

References (39)

1. M.E. Sanders, P.A. Schuyler, and W.D. Dupont The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up Cancer 103 2005 2481 2484
2. M.G. Wallis, K. Clements, O. Kearins, G. Ball, J. Macartney, and G.M. Lawrence The effect of DCIS grade on rate, type and time to recurrence after 15 years of follow-up of screen-detected DCIS Br J Cancer 106 2012 1611 1617
3. E.R. Fisher, R. Leeming, S. Anderson, C. Redmond, and B. Fisher Conservative management of intraductal carcinoma (DCIS) of the breast. Collaborating NSABP investigators J Surg Oncol 47 1991 139 147
4. D. Rosner, R.N. Bedwani, J. Vana, H.W. Baker, and G.P. Murphy Noninvasive breast carcinoma: results of a national survey by the American College of Surgeons Ann Surg 192 1980 139 147
5. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) C. Correa, P. McGale, and C. Taylor Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast J Natl Cancer Inst Monogr 2010 2010 162 177
6. M. Donker, S. Litière, and G. Werutsky Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial J Clin Oncol 31 2013 4054 4059
7. F. Wärnberg, H. Garmo, and S. Emdin Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS trial J Clin Oncol 32 2014 3613 3618
8. B. Fisher, J. Dignam, and N. Wolmark Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17 J Clin Oncol 16 1998 441 452
9. J. Cuzick, I. Sestak, and S.E. Pinder Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial Lancet Oncol 12 2011 21 29
10. T.J. Whelan, J.P. Pignol, and M.N. Levine Long-term results of hypofractionated radiation therapy for breast cancer N Engl J Med 362 2010 513 520
11. J.S. Haviland, J.R. Owen, and J.A. Dewar The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials Lancet Oncol 14 2013 1086 1094
12. D. Spooner, D.D. Stocken, and S. Jordan A randomised controlled trial to evaluate both the role and the optimal fractionation of radiotherapy in the conservative management of early breast cancer Clin Oncol (R Coll Radiol) 24 2012 697 706
13. M. Morrow, J. White, and J. Moughan Factors predicting the use of breast conserving therapy in stage I and II breast carcinoma J Clin Oncol 19 2001 2254 2262
14. A.B.G.M. Nattinger, J. Veum, and D. Yahnke Geographic variation in the use of breast-conserving treatment of breast cancer N Engl J Med 326 1992 1147 1149
15. E. Senkus, S. Kyriakides, F. Penault-Llorca, P. Poortmans, A. Thompson, and S. Zackrisson Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 24 2013 vi7 vi23
16. B.D. Smith, S.M. Bentzen, and C.R. Correa Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline Int J Radiat Oncol Biol Phys 81 2011 59 68
17. Ev. Werkhoven, G. Hart, Hv. Tinteren, P. Elkhuizen, L. Collette, and P. Poortmans Nomogram to predict ipsilateral breast relapse based on pathology review from the EORTC 22881-10882 boost versus no boost trial Radiother Oncol 100 2011 101 107
18. P. Romestaing, Y. Lehingue, and C. Carrie Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France J Clin Oncol 15 1997 963 968
19. TROG (Trans Tasman Radiation Oncology Group) Cancer Research. Active TROG trials, TROG 07.01 A randomized phase III study of radiation doses and fractionation schedules in non-low risk ductal carcinoma in situ (DCIS) of the breast. http://clinicaltrials.gov/ct2/show/NCT00470236?term=boost+AND+DCIS&rank=1 [accessed 19.11.14].
20. D. Azria, D. Cowen, and C. Bourgier Phase III randomized French multicentric study to evaluate the impact of a localized 16-Gy boost after conservative surgery and a 50-Gy whole-breast irradiation in breast ductal carcinoma in situ (the BONBIS trial) J Clin Oncol 29 2011
21. D.F. Stroup, J.A. Berlin, and S.C. Morton Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group JAMA 283 2000 2008 2012
22. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp [accessed 19.11.14].
23. G.H. Guyatt, A.D. Oxman, G.E. Vist, R. Kunz, Y. Falck-Ytter, and P. Alonso-Coello GRADE: an emerging consensus on rating quality of evidence and strength of recommendations BMJ 336 2008 924 926
24. C. Dunne, J.P. Burke, M. Morrow, and M.R. Kell Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ J Clin Oncol 27 2009 1615 1620
25. L. Hathout, T. Hijal, and V. Théberge Hypofractionated radiation therapy for breast ductal carcinoma in situ Int J Radiat Oncol Biol Phys 87 2013 1058 1063
26. J.H. Kim, D.H. Choi, and W. Park Influence of boost radiotherapy in patients with ductal carcinoma in situ breast cancer: a multicenter, retrospective study in Korea (KROG 11-04) Breast Cancer Res Treat 146 2014 341 345
27. N. Lalani, L. Paszat, and R. Sutradhar Long-term outcomes of hypofractionation versus conventional radiation therapy after breast-conserving surgery for ductal carcinoma in situ of the breast Int J Radiat Oncol Biol Phys 2014 Sep 11
28. I. Meattini, L. Livi, and D. Franceschini Role of radiotherapy boost in women with ductal carcinoma in situ: a single-center experience in a series of 389 patients Eur J Surg Oncol 39 2013 613 618
29. A. Omlin, M. Amichetti, and D. Azria Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer Network Lancet Oncol 7 2006 652 656
30. E. Rakovitch, S.A. Narod, and S. Nofech-Moses Impact of boost radiation in the treatment of ductal carcinoma in situ: a population-based analysis Int J Radiat Oncol Biol Phys 86 2013 491 497
31. C. Tunon-de-Lara, C. Lemanski, and C. Cohen-Solal-Le-Nir Ductal carcinoma in situ of the breast in younger women: a subgroup of patients at high risk Eur J Surg Oncol 36 2010 1165 1171
32. C. Vidali, O. Caffo, and C. Aristei Conservative treatment of breast ductal carcinoma in situ: results of an Italian multi-institutional retrospective study Radiat Oncol 7 2012 177
33. E.S. Wai, M.L. Lesperance, and C.S. Alexander Effect of radiotherapy boost and hypofractionation on outcomes in ductal carcinoma in situ Cancer 117 2011 54 62
34. D. Williamson, R. Dinniwell, S. Fung, M. Pintilie, S.J. Done, and A.W. Fyles Local control with conventional and hypofractionated adjuvant radiotherapy after breast-conserving surgery for ductal carcinoma in-situ Radiother Oncol 95 2010 317 320
35. P. Wong, C. Lambert, R.V. Agnihotram, M. David, M. Duclos, and C.R. Freeman Ductal carcinoma in situ - the influence of the radiotherapy boost on local control Int J Radiat Oncol Biol Phys 82 2012 e153 e158
36. R. Yerushalmi, A. Sulkes, and M. Mishaeli Radiation treatment for ductal carcinoma in situ (DCIS): is a boost to the tumor bed necessary? Neoplasma 53 2006 507 510
37. T.B. Julian, S.R. Land, and Y. Wang Is boost therapy necessary in the treatment of DCIS? J Clin Oncol 26 2008 537
38. S.Y. Wang, H. Chu, T. Shamliyan, H. Jalal, K.M. Kuntz, and R.L. Kane Network meta-analysis of margin threshold for women with ductal carcinoma in situ J Natl Cancer Inst 104 2012 507 516
39. A. Monteau, B. Sigal-Zafrani, and Y.M. Kirova Ductal carcinoma in situ of the breast with close or focally involved margins following breast-conserving surgery: treatment with reexcision or radiotherapy with increased dosage Int J Radiat Oncol Biol Phys 75 2009 1021 1028